Company intelligence / Profile preview
BioAxone BioSciences
Boston, Massachusetts, United States
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
BA-210 has completed Phase 1b and Phase 2b clinical trials, reporting safety and clinical data, and received orphan drug and Fast Track designation from the FDA for acute spinal cord injury. BA-1049 and related ROCK2 selective inhibitors have preclinical proof-of-concept and have been out-licensed to Neurelis for further clinical development in CCM.
- Therapeutic areas
- Neurology
- Modalities
- BiologicSmall moleculeRNA therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
NeurelisTanenbaum Open Science Institute, McGill University
Beyond the preview
Go deeper on BioAxone BioSciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioAxone BioSciences.